The short version: the honest timeline for GLP-class compounds is measured in months.
The trials behind the headline numbers ran 48 to 72 weeks — STEP 1 reported roughly 14.9% average weight loss with semaglutide at 68 weeks, SURMOUNT-1 roughly 20.9% with tirzepatide at 72 weeks, and the retatrutide phase 2 roughly 24% at 48 weeks — and in every one of them the first weeks were low-dose titration [stepwise escalation from a deliberately low starting dose], not results.
Healing peptides have no human timeline data at all. GH-axis [growth hormone] markers move in weeks; body composition moves far slower. Anyone promising a transformation on a calendar shorter than the trials ran is selling the calendar, not the compound.
- Trial headline numbers took 48–72 weeks to produce. A marketing timeline shorter than the trial that generated the number is a red flag by arithmetic alone.
- The first weeks on a GLP-class compound are titration by design — low dose, GI [gastrointestinal] adjustment, modest change. The curves diverge meaningfully over months.
- Healing peptides have no human timeline data. Every "feel it in two weeks" claim for BPC-157-class compounds traces to animal models or anecdote, not human trials.
- GH-axis peptides move lab markers before they move mirrors. IGF-1 [insulin-like growth factor 1] changes are measurable within weeks in studies; body-composition shifts take far longer.
- Plateaus are in the trial curves too. Weight-loss trajectories flatten toward a new steady state — that is the pharmacology, not a product defect.
- Non-response is a real, documented outcome. When nothing measurable happens across a reasonable window, stopping is rational — and with gray-market product, a dead vial is always on the suspect list.
The most-gamed number
Every other number a vendor can game sits on a document you can check. The timeline lives in your expectations, which makes it the cheapest one to inflate.
Every other number a vendor can game — purity, fill, testing claims — lives on a document you can check. The timeline lives in your expectations, which makes it the cheapest number to inflate.
Before/after imagery is the standard instrument: two photos, an implied duration, no dosing history, no failure cases. The trial literature is the counterweight, because a registered trial cannot compress its own calendar. When STEP 1 reports its result at week 68, week 68 is what the result cost.
So the most useful habit this page can give you is a single reflex. When you see a claimed result, ask what week the supporting data was measured at. If the answer is "week 60-something" and the marketing implies month two, you have learned what the marketing is worth.
The honest curve
Semaglutide reached roughly 14.9% at 68 weeks, tirzepatide roughly 20.9% at 72, retatrutide roughly 24% at 48. The curve is a slope, not a cliff.
The GLP-class weight-loss compounds — semaglutide, tirzepatide, and the still-unapproved retatrutide — have the best timeline data in the entire peptide market. They ran large randomised trials with published week-by-week curves. Three anchors define the class:
- Semaglutide — STEP 1 reported roughly 14.9% average weight loss at 68 weeks in adults with overweight or obesity, against roughly 2.4% on placebo. GI side effects were the most common adverse events.
- Tirzepatide — SURMOUNT-1 reported roughly 20.9% average loss at the highest dose at 72 weeks.
- Retatrutide — the phase 2 trial reported roughly 24% average loss at the highest dose at 48 weeks. It remains unapproved, with phase 3 still running.
Two structural facts matter more than the headline percentages. First, every trial escalated dose stepwise over months. Participants spent the opening weeks at a fraction of the maintenance dose. The GI side effects that dominate this class are dose-dependent and worst during escalation.
Second, the loss curves are gradual and roughly steady for most of the trial, flattening toward the end. There is no cliff where the weight falls off. There is a slope, gated by titration at the front and a plateau at the back.
Weeks 1–4, 5–12, 13 and beyond
The opening weeks are sub-therapeutic dose and the worst of the GI adjustment. The curves separate through weeks 5 to 12, and most of the published result lives after week 13.
The table below is descriptive, drawn from how the GLP-class trials were structured. It is what the protocols did and what the published curves show, not a protocol for anyone to follow.
| phase | what the trials were doing | what the curves show |
|---|---|---|
| weeks 1–4 | Starting dose, deliberately sub-therapeutic. First escalation steps begin. | Appetite effects arrive early for many participants; measured weight change is modest. GI adjustment — nausea most commonly — is at its worst during these escalation weeks. |
| weeks 5–12 | Stepwise escalation continues toward the maintenance dose. | The treatment and placebo curves separate clearly. Loss accumulates at a steady rate rather than in jumps. |
| weeks 13+ | Participants reach and hold the maintenance dose. | The slope continues for months, then flattens toward a plateau. The headline numbers sit at week 48, 68, or 72 — the far end of this phase, not the start of it. |
Read that last row twice. The gap between week 13 and week 68 is where most of the published result lives. It is precisely the stretch that before/after marketing edits out.
Healing peptides: no timeline
There is no human trial database from which to draw one. Every recovery window in circulation traces back to animal models or anecdote.
Here the honest answer is short. For BPC-157 and the rest of the healing-and-repair category, there is no human trial database from which to draw a timeline at all.
The two-week and four-week recovery windows that circulate in forums trace back to animal models [rodent tendon transection studies, gut lesion models] or to anecdote.
What animal timescales do tell you: in those models, measurable effects on healing markers appeared across days-to-weeks study windows. What they do not tell you: whether the effect exists in humans, at what dose, by what route, or on what calendar.
Rodents heal faster than humans at baseline. The injury models are surgical and standardized in a way real injuries are not. Dosing was proportionally different.
Translating "the rats improved by day 14" into "your tendon improves by week two" is not extrapolation. It is fiction with a citation. Our BPC-157 evidence review grades this literature in full.
Markers first, mirrors later
IGF-1 changes are measurable within weeks in published studies. Body composition moves over months, and by less than the marketing implies.
The growth-hormone-axis compounds — GHRH [growth-hormone-releasing hormone] analogs and secretagogues [compounds that prompt the body to release its own hormone] — have a split timeline worth understanding. In published studies of the approved GHRH analog tesamorelin, IGF-1 changes are measurable within weeks. The axis responds quickly, and blood work shows it.
Body composition is the slow half. The visceral-fat [the fat stored around the organs] reductions in the tesamorelin trials were measured over months of continuous use. Lean-mass changes across this class are slower and smaller than marketing implies.
The practical reading: with GH-axis compounds, weeks-scale expectations belong to lab markers, and months-scale expectations belong to anything you can see. A vendor pitching visible recomposition [muscle up, fat down] in a month is quoting the fast half of the timeline against the slow half of the outcome.
Skin runs on biology's clock
Collagen remodeling runs on multi-week to multi-month cycles whatever is applied. Overnight-glow claims describe hydration and surface effects, not remodeling.
Collagen remodeling — the mechanism behind GHK-Cu and the cosmetic-peptide category — operates on multi-week-to-month cycles regardless of what is applied or injected. Skin turnover runs roughly a month per cycle, and dermal collagen synthesis and reorganization run longer.
The published studies on copper peptides measured changes across multi-week and multi-month windows, consistent with that biology. Overnight-glow claims are describing hydration and surface effects, not remodeling. The remodeling story, where it exists, is a months story.
The plateau conversation
Every GLP-class trial curve flattens toward a new steady state. The plateau is in the data, not evidence of a bad batch or a reason to escalate.
Every GLP-class trial curve flattens. Weight loss decelerates and settles toward a new steady state. The body adapts, energy expenditure shifts, and the compound's effect reaches equilibrium with it.
This is worth internalizing before month six rather than after: the plateau is in the data. It is not evidence of a bad batch, a tolerance crisis, or a need to escalate past studied doses.
In the trials, the plateau is simply what the far end of the curve looks like. Market behavior at the plateau [stacking a second compound, pushing dose] is exactly the point where people leave the evidence base entirely. It is worth reading alongside our side-effects fundamentals.
When no-response is the answer
Non-response is documented in every trial dataset, and an unverified vial is the second suspect. After a comparable window with nothing measurable, stopping is what the evidence supports.
Trial datasets are averages wrapped around a distribution, and the low tail is real. Some participants in every GLP trial lost far less than the mean, on pharmaceutical-grade product with verified dosing. Non-response exists even when everything is exactly what it says it is.
In the research-compound market a second explanation always sits alongside it: the vial. Underdosed, degraded, or misidentified product produces the same nothing that biological non-response does. Without testing, the two are indistinguishable from the inside. A verifiable certificate narrows the suspect list. It never empties it.
Either way, the rational reading is the same. When a window comparable to the relevant data has passed with nothing measurable, continuing to spend money on the same nothing is not persistence. That window is months for the GLP class, and honestly undefined for compounds with no human data.
Stopping is what the evidence supports. In a market this fond of "give it more time," that sentence is the one nobody selling anything will say.
FAQ
How long did the major GLP-1 weight-loss trials run?
STEP 1 reported its semaglutide result at 68 weeks, SURMOUNT-1 reported tirzepatide at 72 weeks, and the retatrutide phase 2 reported at 48 weeks. Those durations are part of the result.
STEP 1 found roughly 14.9% average weight loss in adults with overweight or obesity, against roughly 2.4% on placebo. SURMOUNT-1 found roughly 20.9% at the highest tirzepatide dose.
The retatrutide phase 2 found roughly 24% at its highest dose, and that compound remains unapproved with phase 3 still running.
None of those percentages exists at an earlier timepoint. Every one of these trials escalated the dose stepwise over months, and the loss curves accumulate gradually rather than in jumps. A marketing timeline shorter than the trial that generated the number it quotes is a red flag by arithmetic alone.
Why is week one so unimpressive?
Because trial protocols made it that way on purpose. Starting doses were deliberately sub-therapeutic and escalated stepwise over months. The GI side effects that dominate this class are dose-dependent and worst when a dose level is new.
So the opening weeks combine the lowest dose in the protocol with the roughest adjustment period. That is the least representative stretch of the entire curve.
What the published week 1 to 4 data does show is appetite effects arriving early for many participants while measured weight change stays modest. Nausea is at its worst through the escalation steps.
The treatment and placebo curves only separate clearly across weeks 5 to 12, and loss then accumulates at a steady rate rather than in jumps. Judging a GLP-class compound on week one is judging a titration schedule, not a result.
Is there a real timeline for BPC-157 or other healing peptides?
No human one exists. For BPC-157 and the rest of the healing-and-repair category there is no human trial database from which to draw a timeline at all.
The two-week and four-week recovery windows that circulate in forums trace back to animal models [rodent tendon transection studies, gut lesion models] or to anecdote. What those animal studies do show is measurable effects on healing markers inside their own days-to-weeks windows.
What they cannot show is whether the effect exists in humans, at what dose, by what route, or on what calendar. Rodents heal faster than humans at baseline. The injury models are surgical and standardized in a way real injuries are not. Dosing was proportionally different.
Turning the rats improved by day 14 into your tendon improves by week two is not extrapolation. It is fiction with a citation attached.
What if I see nothing at all?
Both explanations deserve the same weight. Trial datasets are averages wrapped around a distribution, and the low tail is real. Some participants in every GLP trial lost far less than the mean, on pharmaceutical-grade product with verified dosing.
Non-response exists even when everything is exactly what it says it is. In this market a second explanation always sits alongside it: the vial.
Underdosed, degraded, or misidentified product produces the same nothing that biological non-response does, and without testing the two are indistinguishable from the inside. A verifiable certificate narrows the suspect list without emptying it.
Either way the rational reading is the same. When a window comparable to the relevant data has passed, the evidence supports stopping rather than escalating past studied doses. That window is months for the GLP class, and honestly undefined for compounds with no human data.
References
- Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity [STEP 1], N Engl J Med 2021 — nejm.org
- Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1], N Engl J Med 2022 — nejm.org
- Jastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — phase 2, N Engl J Med 2023 — nejm.org
- Our compound-level evidence reviews — retatrutide, graded · BPC-157, graded honestly
disclosure: inside your peptides is published by the owners of the next lab, the only vendor we are paid by elsewhere on this site — none appear on this page. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.